Page 4 - ஓஹியோ நிலை பல்கலைக்கழகம் விரிவான புற்றுநோய் மையம் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Oral targeted therapy found to be an effective treatment option for high-risk hairy cell leukemia The oral targeted therapy drug ibrutinib is an effective treatment option for high-risk hairy cell leukemia, according to a new study conducted by researchers at The Ohio State University Comprehensive Cancer Center - Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC - James). Hairy cell leukemia is a rare form of B-cell blood cancer that is diagnosed in 600 to 800 people annually in the United States. Researchers note that while the disease generally has a good prognosis for the majority of people affected, a small group of patients with variants of the disease do not respond well to existing U.S. Food and Drug Administration (FDA) approved therapies or cannot tolerate the side effects of established therapies.

United statesOhio state universityKerry rogersArthurg jamesEmily hendersonRichardj solove research instituteOhio state university comprehensive cancer centerDrug administrationOhio state college of medicineCancer hospitalResearch instituteOhio stateஒன்றுபட்டது மாநிலங்களில்ஓஹியோ நிலை பல்கலைக்கழகம்கெர்ரி ரோஜர்ஸ்எமிலி ஹென்டர்சன்